Track record · closed signal

Eli Lilly and Company (LLY) — closed signal from March 15, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on June 13, 2026.

Predicted vs. what happened

LLY price · publication thesis → realized outcomesplit-adjusted
$985.08 Published $1,132.84 Target $1,133.00 Window close $1,182.73 Peak
$965.00 – $995.00Entry zone — fair-value band
$985.08Published — price the day we called it
$1,132.84Target — the price the thesis aimed for
$1,182.73Peak — highest point inside the window, not a realized return
$1,133.00Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 74 days.

Peak price
$1,182.73
peak on June 8, 2026 — not a realized return
Peak gain
+20.1%
peak, from the publication price
Window close
$1,133.00
end-of-window price, context only
Days to target
74
Window
March 15, 2026 – June 13, 2026

The thesis — published March 15, 2026

Predicted growth
+15%
over the measurement window
Target price
$1,132.84
the price the thesis aimed for
Entry zone
$965.00 – $995.00
the fair-value band we waited for
Price at publication
$985.08
published March 15, 2026
Confidence
83%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Eli Lilly is recommended for the next 0-3 months because two analysts independently picked it as a safer growth choice. Strong recent business momentum, plus news about a China filing and planned investment, point to rising demand. The recent price dip makes buying more reasonable, but the stock could fall if excitement for GLP-1 drugs cools.

Primary drivers

  • Large-company growth with steady defensive characteristics
  • China filing and planned investment signal expanding demand
  • Strong sales from obesity and diabetes medicines
  • Recent price decline gives a more cautious entry point

How it played out

LLY: target reached in 74 days

Lyra published LLY at $985.08 on 2026-03-15, with 15% expected growth over a short-term window. The thesis pointed to large-company growth with defensive traits, a China filing and planned investment, strong sales from obesity and diabetes medicines, and a recent price decline that gave a more cautious entry point.

Inside the window, LLY rose past the $1132.84 target and reached a $1182.73 peak on 2026-06-08, with a 20.1% peak gain. The target was reached in 74 days. The stock ended at $1133 on 2026-06-13. The thesis played out.

What happened during the window

On 2026-06-08, MarketWatch reported that Lilly shares gained after the company presented Phase 3 retatrutide data at the American Diabetes Association conference. The same report said the highest dose showed 28.3% weight loss after 80 weeks.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All LLY signals